Press Releases

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has begun shipping 20 mg Omeprazole delayed released tablets to its retail customers. This product delivers the same medicine at...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph Papa, Perrigo's Chairman and CEO will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device...

-- Second quarter revenue increased $65 million, or 17 percent, to $435 million -- GAAP net income increased 63 percent to $34 million, or $0.36 per share -- Second quarter cash provided by...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that the Board of Directors has authorized the repurchase of $150 million of the Company's common stock through February 1, 2010...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its second quarter fiscal 2008 on Tuesday, February 5, 2008 at approximately 8:00 a.m. (ET)....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has acquired Galpharm Healthcare, Ltd. for $86 million in cash. Based in Barnsley, Yorkshire, United Kingdom, privately-held...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 26th Annual JPMorgan Healthcare Conference on Wednesday, January 9, at...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the U.S. Food & Drug Administration (FDA) has granted final approval to Dexcel Pharma Technologies, Ltd. for 20 mg Omeprazole...